We are live on ! Find out more
ALPN

Alpine Immune Sciences Inc
ALPN

Delisted

ALPN was delisted on the 17th of May, 2024.

Back to rankings

44 hedge funds and large institutions have $160M invested in Alpine Immune Sciences Inc in 2020 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 13 increasing their positions, 8 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

450% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 2

63% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 8

46% more capital invested

Capital invested by funds: $110M → $160M (+$50.5M)

26% more funds holding

Funds holding: 35 → 44 (+9)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
44
Holders Change
+9
Holders Change %
+25.71%
% of All Funds
0.78%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
11
Increased
13
Reduced
8
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
APM
Avidity Partners Management
Texas
+$4.3M
2
Morgan Stanley
Morgan Stanley
New York
+$3.68M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$2.26M
4
CCM
CAAS Capital Management
New York
+$1.45M
5
PVI
Pura Vida Investments
New York
+$1.35M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$5.89M
2
FCM
Farallon Capital Management
California
-$5.31M
3
SB
Samsara BioCapital
California
-$932K
4
DCM
DAFNA Capital Management
California
-$344K
5
TRCT
Tower Research Capital (TRC)
New York
-$131K
Name Holding Trade Value Shares
Change 		Change in
Stake
VCP
26
Vista Capital Partners
Oregon
$432K +$337K +34,304 New
BlackRock
27
BlackRock
New York
$325K -$49K -4,990 -16%
6CM
28
683 Capital Management
New York
$296K +$231K +23,493 New
Bank of New York Mellon
29
Bank of New York Mellon
New York
$295K +$119K +12,088 +107%
Northern Trust
30
Northern Trust
Illinois
$249K +$49.7K +5,068 +34%
LRIA
31
Leonard Rickey Investment Advisors
Washington
$214K – – –
HW
32
Hancock Whitney
Mississippi
$145K – – –
HP
33
Hikari Power
Japan
$132K – – –
BFM
34
Boothbay Fund Management
New York
$131K +$102K +10,430 New
Citigroup
35
Citigroup
New York
$112K +$87.3K +8,896 New
MIM
36
Monashee Investment Management
Massachusetts
$76K – – –
JP Morgan Chase
37
JP Morgan Chase
New York
$73K +$57.2K +5,827 +194,233%
IC
38
Ikarian Capital
Texas
$60K – – –
Acadian Asset Management
39
Acadian Asset Management
Massachusetts
$33K +$25.9K +2,643 New
SB
40
Samsara BioCapital
California
$5.03K -$932K -95,000 -19%
TRCT
41
Tower Research Capital (TRC)
New York
$4K -$131K -13,355 -98%
Federated Hermes
42
Federated Hermes
Pennsylvania
$3K +$2.02K +206 +687%
Wells Fargo
43
Wells Fargo
California
$1K +$39 +4 +6%
Barclays
44
Barclays
United Kingdom
– -$25K -2,793 Closed
UBS Group
45
UBS Group
Switzerland
– -$12K -1,404 Closed
Royal Bank of Canada
46
Royal Bank of Canada
Ontario, Canada
– -$932 -95 -92%
1
2

ALPN Hedge Fund Activity: Q4 2020 in Review

44 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Alpine Immune Sciences Inc (ALPN) for Q4 2020, worth a combined $160M — up 46% from $110M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new ALPN positions and 2 closed out — a net gain of 9 holders — while 13 added to existing stakes and 8 trimmed.

The largest buyer was Avidity Partners Management, adding an estimated $4.3M. The largest seller was OrbiMed, cutting an estimated $5.89M.

  • 44 institutional investors held Alpine Immune Sciences Inc (ALPN) as of Q4 2020, up from 35 in Q3 2020.
  • Funds reported $160M of Alpine Immune Sciences Inc stock for Q4 2020, up 46% quarter-over-quarter.
  • 11 funds opened new Alpine Immune Sciences Inc positions in Q4 2020 and 2 closed out, a net change of +9 holders.
  • The largest Alpine Immune Sciences Inc buyer in Q4 2020 was Avidity Partners Management, an estimated $4.3M added.
  • The largest Alpine Immune Sciences Inc seller in Q4 2020 was OrbiMed, an estimated $5.89M sold.

Based on aggregated 13F filings for Q4 2020.